Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intravitreal steroid versus macular laser for treatment of diabetic macular edema.

Literature DB >> 19640339

Intravitreal steroid versus macular laser for treatment of diabetic macular edema.

Abstract

Diabetic macular edema is a leading cause of vision loss in the United States. Focal/grid laser photocoagulation has been the gold standard for treatment over the past two decades. Intravitreal pharmacologic treatments increasingly have been used over the past 5 years. Various studies have shown the possible benefits of intravitreal corticosteroids and anti-vascular endothelial growth factors in the treatment of diabetic macular edema. However, focal/grid laser photocoagulation continues to be the only proven safe and effective treatment for diabetic macular edema.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2009 PMID： 19640339 DOI： 10.1007/s11892-009-0042-5

Source DB: PubMed Journal: Curr Diab Rep ISSN： 1534-4827 Impact factor: 4.810

22 in total

1. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.

Authors: Emmett T Cunningham; Anthony P Adamis; Michael Altaweel; Lloyd P Aiello; Neil M Bressler; Donald J D'Amico; Mauro Goldbaum; David R Guyer; Barrett Katz; Manju Patel; Steven D Schwartz
Journal: Ophthalmology Date: 2005-10 Impact factor: 12.079

2. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.

Authors: Ingrid U Scott; Allison R Edwards; Roy W Beck; Neil M Bressler; Clement K Chan; Michael J Elman; Scott M Friedman; Craig Michael Greven; Raj K Maturi; Dante J Pieramici; Michel Shami; Lawrence J Singerman; Cynthia R Stockdale
Journal: Ophthalmology Date: 2007-08-15 Impact factor: 12.079

3. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).

Authors: I M Stratton; C A Cull; A I Adler; D R Matthews; H A W Neil; R R Holman
Journal: Diabetologia Date: 2006-05-31 Impact factor: 10.122

4. Blindness caused by diabetes--Massachusetts, 1987-1994.

Authors:
Journal: MMWR Morb Mortal Wkly Rep Date: 1996-11-01 Impact factor: 17.586

5. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis.

Authors: R O Graham; G A Peyman
Journal: Arch Ophthalmol Date: 1974-08

Review 6. Drug delivery methods for posterior segment disease.

Authors: Jason Hsu
Journal: Curr Opin Ophthalmol Date: 2007-05 Impact factor: 3.761

7. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.

Authors: A S Berger; C K Cheng; P A Pearson; P Ashton; P A Crooks; T Cynkowski; G Cynkowska; G J Jaffe
Journal: Invest Ophthalmol Vis Sci Date: 1996-10 Impact factor: 4.799

8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors:
Journal: Lancet Date: 1998-09-12 Impact factor: 79.321